Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625142 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBTACR1CACNA2D1 | |
| SCHEMBL5551081 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBTACR1CACNA2D1 | |
| SCHEMBL6628577 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBTACR1CACNA2D1 | |
| SCHEMBL6626285 | 0.90 | SLC6A9 (0.39) | SLC6A9HSD17B10ALBTACR1S1PR1 | |
| SCHEMBL21185731 | 0.87 | SLC6A9 (0.44) | SLC6A9HSD17B10ALBTACR1CACNA2D1 | |
| SCHEMBL300399 | 0.85 | — | — | |
| SCHEMBL9159811 | 0.85 | SLC6A9 (0.43) | SLC6A9HSD17B10ALBTACR1CACNA2D1 | |
| SCHEMBL6628233 | 0.85 | SLC6A9 (0.36) | SLC6A9HSD17B10ALBTACR1S1PR1 | |
| SCHEMBL15780321 | 0.85 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBTACR1 | |
| SCHEMBL2779265 | 0.85 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0325762-B1 | Macrocyclic chelating agents and chelates thereof | BRACCO SPA (IT) | 1995-03-22 | — | — | EP | claimed |
| EP-0325762-A1 | Macrocyclic chelating agents and chelates thereof | BRACCO S.p.A. (IT) | 1989-08-02 | — | — | EP | claimed |
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-0874645-B1 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-0882010-B1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-05-02 | — | — | EP | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
| EP-0325762-B1 | Macrocyclic chelating agents and chelates thereof | BRACCO SPA (IT) | 1995-03-22 | — | — | EP | disclosed |
| US-5132409-A | Derivatives of 1,4,7,10-Tetraazacyclododecane | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1992-07-21 | — | — | US | disclosed |
| EP-0325762-A1 | Macrocyclic chelating agents and chelates thereof | BRACCO S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | SLC6A9 368/4885HSD17B10 1741/4885ALB 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.